Literature DB >> 15221660

Benign prostate hyperplasia: evaluation of treatment response with DCE MRI.

J T Heverhagen1, H von Tengg-Kobligk, K T Baudendistel, G Jia, H Polzer, H Henry, A L Levine, T J Rosol, M V Knopp.   

Abstract

Benign prostate hyperplasia (BPH) is a major disease and its non-surgical therapy a major area of interest. The purpose of this study was to establish perfusion parameters in beagles with BPH using dynamic contrast-enhanced (DCE) MRI and to investigate changes due to the effects of finasteride treatment. Twelve male beagles (mean age 4.4 +/- 0.9,years) were divided into a control and treatment group that received a daily dose of 1 mg/kg finasteride. DCE MRI was carried out in a clinical scanner using a 3D spoiled gradient echo sequence prior to and during treatment. 0.2 mmol/kg contrast agent (gadoteridol) was administered with an injection rate of 0.2 ml/s followed by a 15 ml flush of saline. Contrast enhancement was evaluated by pharmacokinetic mapping of a two-compartment model with colour overlay images in addition to regional ROI analysis. Quantitative parameters were defined by the amplitude of contrast enhancement A, the exchange rate k(ep) and the time to maximum signal enhancement. Dynamic contrast-enhanced MRI investigations of the prostate revealed two distinct zones, an inner, periurethral zone and an outer, parenchymal zone. The periurethral zone is highly vascularized, whereas the parenchymal zone is moderately vascularized when compared to other parenchymal organs. During treatment, in the parenchymal zone the intensity of enhancement (amplitude A) and the time to maximum signal enhancement increased, while the exchange rate k(ep) decreased. Dynamic contrast-enhanced MRI of BPH reveals distinct differences between individual zones within the prostate. Moreover, changes during successful treatment suggest increased blood volume per volume of tissue and decreased vessel leakiness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221660     DOI: 10.1007/s10334-004-0040-1

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  19 in total

1.  Quantification of prostate shrinkage after microwave thermotherapy: a comparison of calculated cell-kill versus 3D transrectal ultrasound planimetry.

Authors:  Aswin L Hoffmann; M Pilar Laguna; Jean J M C H de la Rosette; Hessel Wijkstra
Journal:  Eur Urol       Date:  2003-02       Impact factor: 20.096

2.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

3.  Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.

Authors:  R J Moore; J M Gazak; J F Quebbeman; J D Wilson
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

4.  Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations.

Authors:  M Murakoshi; R Inada; M Makino; M Suzuki; M Mieda; S Honma; H Yamanaka
Journal:  Acta Pathol Jpn       Date:  1990-12

5.  A prospective evaluation of detrusor ultrastructural changes in bladder outlet obstruction.

Authors:  R D Brierly; R G Hindley; E McLarty; D M Harding; P J Thomas
Journal:  BJU Int       Date:  2003-03       Impact factor: 5.588

6.  Experimentally-induced prostatic hyperplasia in young beagles: a model to evaluate the chemotherapeutic effects of gossypol.

Authors:  W Y Chang; F Shidaifat; C J Chang; S K Kulp; Y Sugimoto; H Canatan; R W Brueggemeier; Y C Lin
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1996-06

Review 7.  Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Peter L Choyke; Andrew J Dwyer; Michael V Knopp
Journal:  J Magn Reson Imaging       Date:  2003-05       Impact factor: 4.813

Review 8.  Investigation of benign prostatic hyperplasia.

Authors:  Andrea Tubaro; Alberto Trucchi; Lucio Miano
Journal:  Curr Opin Urol       Date:  2003-01       Impact factor: 2.309

9.  Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate.

Authors:  C B Brendler; S J Berry; L L Ewing; A R McCullough; R C Cochran; J D Strandberg; B R Zirkin; D S Coffey; L G Wheaton; M L Hiler; M J Bordy; G D Niswender; W W Scott; P C Walsh
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

10.  Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia.

Authors:  S J Berry; D S Coffey; J D Strandberg; L L Ewing
Journal:  Prostate       Date:  1986       Impact factor: 4.104

View more
  4 in total

1.  Precision analysis of kinetic modelling estimates in dynamic contrast enhanced MRI.

Authors:  Dieter De Naeyer; Yves De Deene; Wim P Ceelen; Patrick Segers; Pascal Verdonck
Journal:  MAGMA       Date:  2011-01-08       Impact factor: 2.310

2.  Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.

Authors:  Yae Won Park; Sung Soo Ahn; Ju Hyung Moon; Eui Hyun Kim; Seok-Gu Kang; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  Neuroradiology       Date:  2021-03-23       Impact factor: 2.804

3.  Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.

Authors:  J G Nam; K M Kang; S H Choi; W H Lim; R-E Yoo; J-H Kim; T J Yun; C-H Sohn
Journal:  AJNR Am J Neuroradiol       Date:  2017-10-26       Impact factor: 3.825

4.  Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer.

Authors:  Rajakumar Nagarajan; Daniel Margolis; Steven Raman; Ke Sheng; Christopher King; Robert Reiter; M Albert Thomas
Journal:  Adv Urol       Date:  2011-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.